Learning Objectives:

At the end of this presentation participants will be able to:

•Describe the prevalence of illicitly manufactured fentanyl in the US drug supply.
•Explain the major pharmacologic properties of both fentanyl and buprenorphine.
•Recall at least two “tools” that can help guide the process of starting buprenorphine treatment.
•Identify at least three medications that have been proven to support management of withdrawal symptoms during the buprenorphine initiation process.

Session Faculty:
Kristin Wason, MSN, NPC, CARN has no relevant financial relationship to disclose.